Cancer Research

Business

IDEXX Laboratories Posts Strong Q4 Growth, Unveils Ambitious 2026 Outlook on Diagnostic Innovation

IDEXX Laboratories (IDXX) reported robust double-digit growth for Q4 2025, driven by record placements of its premium diagnostic instruments and expanding test utilization. While acknowledging persistent softness in U.S. veterinary visit volumes, the company outlined a confident initial 2026 forecast, banking on its innovation pipeline and the transformative impact of its inVue Dx system.

Feb 2, 2026

Business

The Incentive Gap: Why Most Companies' Sales Compensation Plans Are Failing to Deliver Growth

New research reveals a stark disconnect: while a majority of firms are ramping up investment in incentive pay to fuel growth, widespread execution errors are rendering these costly programs ineffective, leaving potential revenue on the table.

Feb 2, 2026

Business

Piper Sandler Trims Price Target for Black Diamond Therapeutics Amid Model Review, Despite Recent Clinical Wins

Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.

Feb 2, 2026

Business

Quince Therapeutics Plummets After Late-Stage Trial of A-T Therapy Fails to Hit Targets

Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.

Feb 2, 2026

US

Government Shutdown Looms, Grammys Spotlight Immigration as Protests Sweep Nation

A partial government shutdown triggers furloughs, the Grammys become a platform for political statements, and nationwide protests over immigration policy unfold amid a severe winter storm's aftermath.

Feb 2, 2026

Business

Eli Lilly Bets Nearly $2 Billion on Repertoire Immune Medicines to Pioneer Next-Generation Autoimmune Therapies

Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.

Feb 2, 2026

Business

Cogent Biosciences Gains Key FDA Designations for Bezuclastinib, Spotlighting GIST Treatment Potential

Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.

Feb 2, 2026

Business

Wall Street's Uncomfortable Truth: Three High-Profile Stocks Analysts Are Quietly Souring On

In a rare break from Wall Street's typically optimistic consensus, a handful of prominent stocks are receiving bearish price targets that signal deep-seated concerns. We examine the challenges facing Deckers, MSC Industrial, and Guardant Health, and why investors might want to look elsewhere.

Feb 2, 2026

Business

Immunocore's Valuation Puzzle: Short-Term Volatility Masks Long-Term Promise

Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.

Feb 2, 2026

Business

FDA Grants Breakthrough Status to Cogent Biosciences' GIST Combo Therapy, Accelerating Path to Market

Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.

Feb 2, 2026

Business

Insider Bets on Asia's Growth Engines: Techwing, Graphy, and Nanjing Leads Biolabs in Focus

Amidst a cautiously optimistic Asian market, companies where executives and directors hold significant stakes are drawing investor attention. We examine three high-conviction plays in semiconductors, 3D printing, and biotech where insider ownership aligns with explosive growth forecasts.

Feb 2, 2026

Business

IDEAYA Biosciences: A Buying Opportunity After the Pullback, or Priced for Perfection?

IDEAYA Biosciences shares have retreated from recent highs, presenting investors with a dilemma. While long-term performance remains strong, its premium valuation and significant net losses raise questions about whether the current price already reflects its promising pipeline.

Feb 2, 2026

US

RFK Jr. on Family Ties After Tragic Loss: A Kennedy Divide Widened by Politics and Personal Grief

In an exclusive interview, Robert F. Kennedy Jr. addresses the state of his relationship with cousin Caroline Kennedy following the death of her daughter, Tatiana Schlossberg, last December. The tragedy unfolds against a backdrop of deep political rifts within America's most storied political dynasty.

Feb 2, 2026

US

RFK Jr. Breaks Silence on Kennedy Family Rift Amidst Cousin's Tragic Passing

Health and Human Services Secretary Robert F. Kennedy Jr. has publicly addressed the deep divisions within America's most storied political family, following the death of his cousin Tatiana Schlossberg and amidst ongoing policy controversies that have placed him at odds with his relatives.

Feb 2, 2026

Business

Geron Sees Price Target Cut to $3 by TD Cowen Ahead of Q4, But Buy Rating Stays

Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.

Jan 30, 2026

Business

Cash Flow Caution: Three High-Yield Stocks Facing Headwinds

Robust cash generation is a hallmark of financial health, but it doesn't guarantee future performance. We examine three companies with strong free cash flow margins whose underlying challenges—from competitive pressures to growth concerns—suggest investors should look closer before buying.

Jan 30, 2026

Business

Guggenheim More Than Doubles Erasca Price Target to $12 on Clinical Progress and Pipeline Updates

Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.

Jan 30, 2026

Business

Genmab Shares Face Target Cut After EPKINLY Trial Misses Survival Goal, But Analysts Keep Faith

H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.

Jan 30, 2026

Business

Bank of America Lifts Target on Xencor Amid Broader Biotech Sector Optimism

Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.

Jan 30, 2026

Business

China's Tech Giants Secure Massive NVIDIA H200 Chip Orders Amid Shifting Semiconductor Policy

Chinese authorities have approved ByteDance, Alibaba, and Tencent to purchase over 400,000 of NVIDIA's flagship H200 AI chips, signaling a pragmatic shift in Beijing's approach to balancing advanced U.S. technology with domestic chip ambitions.

Feb 3, 2026